Mohamed Eslam, MD
Internal Medicine · Tulsa, OKNPI 1710440631
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 423 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 423 payments — averaging $25.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$1K
- AbbVie$1K
- Pfizer$873
- Amgen$688
- Lilly USA, LLC$602
- plus $5K from 32 others
What the payments were for
- Food & beverage$10,918100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 48 | $1,572 |
| Novo Nordisk | 55 | $1,257 |
| AbbVie | 64 | $1,108 |
| Pfizer | 32 | $873 |
| Amgen | 25 | $688 |
| Lilly USA, LLC | 33 | $602 |
| Bayer | 23 | $580 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $376 |
| Axsome Therapeutics, Inc. | 8 | $353 |
| Abbott | 4 | $297 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $270 |
| Otsuka America Pharmaceutical, Inc. | 8 | $259 |
| Idorsia Pharmaceuticals US Inc | 10 | $255 |
| Boston Scientific | 2 | $234 |
| GSK | 14 | $212 |
| Esperion Therapeutics, Inc. | 5 | $192 |
| Eisai Inc. | 7 | $159 |
| Boehringer Ingelheim | 9 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $146 |
| Johnson & Johnson | 7 | $130 |
| Hydrocision, Inc. | 1 | $127 |
| Teva Pharmaceuticals USA, Inc. | 5 | $124 |
| Sanofi | 1 | $124 |
| Penumbra, Inc. | 1 | $119 |
| Lundbeck LLC | 4 | $104 |
| Vanda Pharmaceuticals Inc. | 3 | $92 |
| Sumitomo Pharma America, Inc. | 4 | $89 |
| Exact Sciences | 5 | $81 |
| Dexcom, Inc. | 3 | $49 |
| Intra-sana Laboratories | 3 | $46 |
| Currax Pharmaceuticals LLC | 3 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Novartis | 1 | $33 |
| Astellas Pharma US Inc | 1 | $31 |
| Irhythm Technologies, Inc. | 2 | $30 |
| Lexicon Pharmaceuticals, Inc. | 1 | $29 |
| Mylan Specialty L.p. | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,918 in reported general payments places this provider in the 95th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 91 | $104,787 |
| JardianceEmpagliflozin | 79 | $81,168 |
| FarxigaDapagliflozin Propanediol | 76 | $68,264 |
| EliquisApixaban | 81 | $46,225 |
| RybelsusSemaglutide | 19 | $34,269 |
| MounjaroTirzepatide | 20 | $21,105 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $17,912 |
| XareltoRivaroxaban | 17 | $17,723 |
| Rosuvastatin Calcium | 372 | $5,852 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $4,833 |
| Atorvastatin Calcium | 280 | $3,832 |
| Olmesartan Medoxomil | 95 | $3,586 |
| Gabapentin | 248 | $3,164 |
| PremproEstrogen,con/M-Progest Acet | 12 | $2,792 |
| Omeprazole | 138 | $2,350 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,257 | $139,056110 claims |
| Boehringer IngelheimJardiance | $150 | $81,16879 claims |
| AstraZenecaFarxiga | $1,572 | $68,26476 claims |
| PfizerEliquis, Prempro | $873 | $49,01793 claims |
| Lilly USA, LLCMounjaro | $602 | $21,10520 claims |
| GSKTrelegy Ellipta | $212 | $17,91226 claims |
| Johnson & JohnsonXarelto | $130 | $17,72317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Tulsa
- Jesse RichardsTulsa$279K
- Madhuri LadTulsa$173K
- Stacy ChronisterTulsa$163K
- Layth Al AttarTulsa$35K
- Gerard McNultyTulsa$27K
- Peter LantzTulsa$23K
- Sudip TripathyTulsa$21K
- John RuffingTulsa$21K
- Joseph ReeseTulsa$18K
- Mark GallesTulsa$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.